证券代码： 002399 证券简称：海普瑞 公告编号： 2025-027 深圳市海普瑞药业集团股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）2024年年度权益 分派方案已获2025年5月22日召开的公司2024年年度股东大会审议通过，现将权益 分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司股东大会审议通过的利润分配方案具体内容 公司2024年年度利润分配方案为：以公司总股本1,467,296,204股（其中含A股 1,247,201,704股，H股220,094,500股）为基数，向全体股东每10股派发现金红利人 民币2.50元（含税），不送红股，不以资本公积金转增股本，剩余利润作为未分配 利润留存。 2、自利润分配方案披露至实施期间，公司股本总额未发生变化。 H股股东：权益分派的详细安排请见公司披露于香港联合交易所网站 www.hkexnews.hk的相关公告。 三、分红派息日期 本次A股权益分派股权登记日为：2025年7月4日，除权除息日 ...

证券代码： 002399 证券简称：海普瑞 公告编号：2025-026 深圳市海普瑞药业集团股份有限公司 关于依诺肝素钠注射液获得EMA新增生产商批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"海普瑞"或"公司"）近日 收到欧洲药品管理局（以下简称"EMA"）签发的关于依诺肝素钠注射液新增成 品制造商的批准通知。现将相关情况公告如下： 一、药品相关情况 （一）通用名称：依诺肝素钠 （二）商品名：Inhixa 三、风险提示 本次坪山制剂生产场地的获批对公司现阶段业绩暂不会产生重大影响。由于 医药行业的特点，药品的生产和销售可能受到政策法规调整、市场环境变化等不确 定因素的影响。敬请广大投资者谨慎决策，注意投资风险。 （六）生产场地地址：中国深圳市坪山区坑梓街道荣田路 1 号 （七）批准文号：EMA/VR/0000262543 二、对公司的影响 海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动，首期新建三 条预灌封生产线设计产能为3.3亿支/年，按照中国、欧美药品法规标准设计建造， 用于生产依诺肝素 ...

Group 1 - Company Xi Zhong Technology proposed to repurchase shares worth between 75 million and 150 million yuan using excess funds and self-owned funds [1] - Company Yongxi Electronics expects a revenue growth of 16.6% to 28.88% in the first half of the year, with projected revenue between 1.9 billion and 2.1 billion yuan [2] - Company Jingyi Equipment anticipates a revenue increase of 36.54% to 42.48%, with expected revenue between 690 million and 720 million yuan [2][3] Group 2 - Company Haipuri received approval from the European Medicines Agency (EMA) for a new production line for Enoxaparin Sodium injection, with an annual capacity of 330 million doses [4] - Company Inner Mongolia Xinhua plans to merge its wholly-owned subsidiaries to optimize resource allocation and improve operational efficiency [5] - Company Cloud Chemical intends to sign daily related transaction framework agreements with its controlling shareholder to reduce operational costs [7] Group 3 - Company China Software received approval from the China Securities Regulatory Commission for a specific stock issuance [8] - Company Wankong Intelligent's subsidiary won a bid for a project with the State Grid worth approximately 12.17 million yuan [9] - Company Lianlong obtained a patent for an anti-aging agent, which is expected to enhance its product offerings in polymer materials [11] Group 4 - Company Yunlu plans to increase its shares by 4 million to 12 million yuan through stock purchases by its executives [12] - Company Enhua Pharmaceutical's chairman increased his stake by 237,900 shares [14] - Company Daqin Railway announced the resignation of its general manager due to retirement [15] Group 5 - Company Hefei Urban Construction signed a land use rights transfer contract for an industrial site with an area of 78,561.78 square meters, with a payment of 103 million yuan due by July 13, 2025 [16] - Company Taiji Group received a government subsidy of 20 million yuan, representing 75.04% of its projected net profit for 2024 [17] - Company Guodian Nanrui elected a new chairman, Zheng Zongqiang, while he resigned from his previous roles [19] Group 6 - Company Xinhua Medical received a medical device registration certificate for a thromboelastography testing kit [20] - Company Baotailong's subsidiary obtained a mining license for a graphite mine with a production capacity of 2 million tons per year [21] - Company Zejing Pharmaceutical received approval for clinical trials of its innovative cancer treatment drugs [22] Group 7 - Company Aojing Medical's artificial bone repair material received registration approval in Vietnam [23] - Company Chengjian Development received a cash dividend of 90.2169 million yuan from Guoxin Securities [24] - Company Rili Technology proposed a share repurchase plan worth between 10 million and 20 million yuan [25] Group 8 - Company Deshi General Institute received approval to issue up to 1 billion yuan in technology innovation bonds [44] - Company Tongding Interconnect plans to bid for two procurement projects worth approximately 717 million yuan [46] - Company Bangji Technology plans to acquire multiple agricultural companies [46]

Core Viewpoint - The company received approval from the European Medicines Agency (EMA) for a new manufacturer of Enoxaparin Sodium Injection, enhancing its production capacity and market competitiveness [1] Group 1: Approval Details - The approved product is Enoxaparin Sodium Injection, marketed under the name Inhixa [1] - The injection comes in various specifications: 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 120mg/0.8ml, and 150mg/1ml [1] - The new manufacturer is Shenzhen Hepalink Pharmaceutical Group Co., Ltd., located at No. 1 Rongtian Road, Kengzi Street, Pingshan District, Shenzhen, China [1] Group 2: Strategic Implications - The approval will support the company's strategy for internationalization of its formulations [1] - It will provide sufficient production capacity to enhance the company's competitiveness in the market [1]

北京中银（深圳）律师事务所 关于深圳市海普瑞药业集团股份有限公司 2024 年年度股东大会的 法律意见书 地址：深圳市福田区益田路 6003 号荣超商务中心 A 座 5、6 层 电话：（86-755）82531588 传真：（86-755）82531555 邮编：518026 北京中银（深圳）律师事务所 法律意见书 北京中银（深圳）律师事务所 关于深圳市海普瑞药业集团股份有限公司 2024 年年度股东大会的 法律意见书 致：深圳市海普瑞药业集团股份有限公司 北京中银（深圳）律师事务所（以下简称"本所"）接受深圳市海普瑞药业集 团股份有限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称《公司法》）《上市公司股东大会规则》等法律、法规、规章和其他规范性文 件以及《深圳市海普瑞药业集团股份有限公司章程》（以下简称《公司章程》） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤 ...

深圳市海普瑞药业集团股份有限公司 证券代码：002399 证券简称：海普瑞 公告编号：2025-025 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议召开时间： （1）现场会议时间：2025年5月22日下午14:00 3、会议召开方式：现场表决与网络投票相结合的方式 4、会议召集人：公司第六届董事会 5、会议主持人：董事长李锂 6、召开会议的通知已于2025年3月29日刊登在《证券时报》《中国证券报》 《上海证券报》《证券日报》及巨潮资讯网（www.cninfo.com.cn）上（2025-009）。 本次股东大会的召集及召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所股票上市规则》等法律法规、规范性文件及《深圳市 海普瑞药业集团股份有限公司章程》的有关规定。 二、会议出席情况 1、股东出席情况 （2）网络投票时间：2025年5月22日 公司A股股东通过深圳证券交易所交易系 ...

Financial Performance - In 2024, the Company reported revenue of RMB 5,258,919, a decrease of 3.2% compared to RMB 5,430,974 in 2023[15] - The profit before tax for 2024 was RMB 726,229, recovering from a loss of RMB 928,334 in 2023[15] - The profit attributable to owners of the Company for 2024 was RMB 646,742, compared to a loss of RMB 783,258 in 2023[15] - Basic earnings per share for 2024 was RMB 0.44, an improvement from a loss of RMB 0.53 in 2023[15] - The Group achieved a revenue of approximately RMB5,258.9 million and a net profit of approximately RMB624.9 million, marking significant year-on-year growth[27] - The Group achieved an operating revenue of approximately RMB5,258.9 million in 2024, representing a year-on-year decrease of approximately 3.2%[49] - Gross profit increased by approximately 84.9% year-on-year to approximately RMB1,739.3 million, with a gross margin of approximately 33.1%, up by approximately 15.8 percentage points year-on-year[49] - The Group turned from loss into profit, reporting a net profit of approximately RMB624.9 million, with net profit attributable to equity holders of the Company at approximately RMB646.7 million[49] - The Group's overall operating revenue was approximately RMB5,258.9 million, a year-on-year decrease of approximately 3.2%, while gross profit increased by approximately 84.9% to RMB1,739.3 million, with a gross margin of approximately 33.1%[52] - The impairment amount for inventory in 2024 was only approximately RMB7.6 million, significantly lower than RMB855.4 million in 2023, contributing to improved gross profit margins[102] - Finance costs decreased by approximately RMB82.9 million to approximately RMB145.2 million, representing a decrease of approximately 36.3% compared to 2023[106] - Income tax expense for the reporting period was approximately RMB 101.3 million, compared to a tax credit of approximately RMB 126.2 million in 2023[111] Assets and Liabilities - Total assets decreased to RMB 17,343,524 in 2024 from RMB 19,203,417 in 2023, reflecting a decline of 9.7%[16] - Total liabilities also decreased to RMB 5,141,403 in 2024, down from RMB 7,215,040 in 2023, a reduction of 28.8%[16] - The asset-liability ratio was approximately 29.6% as of December 31, 2024, down from approximately 37.6% in 2023[127] - As of December 31, 2024, the group's cash and bank balances were approximately RMB 1,421.8 million, down from approximately RMB 1,765.6 million in 2023[118] - The group recorded short-term loans of approximately RMB 2,367.2 million and long-term loans of approximately RMB 1,081.0 million as of December 31, 2024[119] - The Group's total financial indebtedness decreased to approximately RMB3,544.8 million from RMB5,562.8 million as of December 31, 2023, representing a reduction of about 36.4%[140] - The Group's interest-bearing bank and other borrowings were approximately RMB3,448.2 million as of December 31, 2024, down from RMB5,434.6 million in the previous year, indicating a decrease of approximately 36.5%[140] - The Group's lease liabilities decreased to RMB96.6 million as of December 31, 2024, from RMB128.2 million as of December 31, 2023, a reduction of about 24.6%[140] Business Strategy and Operations - The Company emphasized its commitment to innovation-driven and globalization strategies, enhancing its global marketing network[24] - The Company aims to consolidate its leading position in the international heparin market through a vertically integrated industry chain[24] - The Company has transformed from a local enterprise to a global leader in the heparin field over the past decade[24] - The heparin business, as the core pillar, set a historical best performance with a significant leap in market share due to enhanced local operations and market penetration[28] - The CDMO business exhibited strong growth, forming a "dual-wheel drive" development pattern, enhancing market competitiveness and overall performance[29] - The Group plans to further optimize the vertical integration of the heparin industry chain to enhance product competitiveness and market share[37] - The Group aims to accelerate the clinical progress of the H1710 project and explore more opportunities for innovative drug research and development[37] - The Group will strengthen the diversified operations of SPL and Cytovance to promote sustained growth in CDMO and specialty product businesses[37] - The Group remains cautiously optimistic about its business prospects while focusing on cost control to ensure stable financial benefits and cash flow levels[38] - The Group plans to further optimize the heparin supply chain's vertical integration to enhance product competitiveness and market share[40] - The CDMO business experienced rapid growth during the Reporting Period, with both business revenue and gross margin increasing year-on-year[48] - The Group aims to enhance its global presence and brand influence while increasing market penetration in the heparin industry despite trade protectionist challenges[82] - The Group plans to optimize marketing strategies and improve sales share in the finished dosage form business, targeting growth in Asia-Pacific and Latin America[84] Research and Development - The innovative drug H1710 project completed its IND application in China, marking a breakthrough in the Group's innovation efforts[30] - H1710, a candidate drug targeting heparanase, has shown significant anti-tumor effects in various animal models and received approval for clinical trials from the National Medical Products Administration in February 2025[73] - Oregovomab, an anti-CA125 immunotherapy drug, completed a Phase II clinical trial and is under further evaluation after not meeting its intended objectives in Phase III trials[74] - RVX-208 (Apabetalone) completed Phase III clinical trial (BETonMACE) to reduce major adverse cardiovascular events in high-risk patients, receiving FDA Breakthrough Therapy Designation[79] - The Group is actively exploring cooperation opportunities to accelerate the strategic layout of innovative drugs and diversify commercialization capabilities[76] Market Performance - The annual sales volume of enoxaparin sodium formulations achieved double-digit growth, successfully expanding the global formulation market share[47] - The Group maintained its market share as one of the top two in Europe for enoxaparin sodium formulation, successfully increasing the bid-winning rate to expand market share[56] - In the United States, the Group's sales revenue showed impressive growth, benefiting from a dual strategy of self-operated and agency-driven approaches[57] - The Group obtained market entry licenses in Thailand and New Zealand, enhancing its international market share and creating new sales opportunities[61] - The Group is actively working to increase market share in China while addressing pricing pressures from the national centralized procurement platform[58] Management and Governance - The Group's executive directors have over 30 years of experience in the pharmaceutical industry, contributing to strategic planning and decision-making[142] - The Group's strategic focus includes innovative drugs and CDMO sectors, with active participation from executive directors in formulating and implementing business strategies[149][152] - The Group's management team includes experienced professionals who oversee various aspects of the business, including production capacity, logistics, and human resources[152][149] - Ms. Li Tan has over 30 years of experience in the pharmaceutical industry and is responsible for major decisions and business development activities[155] - Mr. Shan Yu also has over 30 years of experience in the pharmaceutical industry, overseeing capacity, safety, logistics, and external matters[156] - Mr. Zhang Ping has extensive experience in manufacturing and operations, having served as General Manager at Hangzhou Innovax Biotech Co., Ltd. and Head of Industry Affairs at Sanofi, managing seven plants in China[157][161] - Dr. Lu Chuan has been an independent non-executive director since December 2019 and has extensive experience in investment banking and management[158][162] - Mr. Huang Peng, an independent non-executive director, has a Ph.D. in Management and has served as an independent director for multiple companies listed on the Shanghai and Shenzhen Stock Exchanges[164] - Mr. Yi Ming, another independent non-executive director, has a Master's degree in Finance and has held senior management positions in asset management companies[165] - Mr. Zheng Zehui, chairman of the Supervisory Committee, has served as general manager of URIT Medical Electronic Sales Co., Ltd. and has a background in biochemistry[166] - Ms. Tang Haijun has been with the company since February 2001 and serves as a Supervisor, managing the GXP document control department[167] Corporate Actions - The Company completed its initial public offering and listing of its A Shares on the Shenzhen Stock Exchange on May 6, 2010, and its H Shares on the Hong Kong Stock Exchange on July 8, 2020[181] - The Group proposed a final cash dividend of RMB2.5 (tax inclusive) per ten ordinary shares, compared to nil in 2023[187] - The Group has not incurred any additional costs specifically attributable to environmental compliance during the year ended December 31, 2024[191] - The Group has no current plans for significant acquisitions or capital asset investments as of December 31, 2024[138] Reporting and Analysis - A detailed analysis of the Group's revenue and operating profit for the year ended December 31, 2024, is provided in the "Management Discussion and Analysis" section of the annual report[182] - The business review includes discussions on principal risks and uncertainties faced by the Group, as well as an analysis of performance using financial key performance indicators[183] - Important events affecting the Group during the year ended December 31, 2024, are highlighted in the annual report[183] - Future developments in the Group's business are indicated in the annual report[183] - The Group's financial performance indicators and major events impacting the business are discussed in the "Chairman's Statement" and "Management Discussion and Analysis" sections of the annual report[186] - The Group's audited consolidated results for the reporting period are detailed on pages 85 to 86 of the annual report[188] - The Group's reserves and movements for the current and prior years are presented in the consolidated statement of changes in equity on pages 89 to 90 of the annual report[200]

Core Viewpoint - The recent financial report of Haiprui (002399) shows a year-on-year increase in both revenue and net profit for Q1 2025, indicating stable performance despite some declines in profit margins and cash flow metrics [1]. Financial Performance - Total revenue for Q1 2025 reached 1.394 billion yuan, a 1.53% increase compared to 1.373 billion yuan in Q1 2024 [1]. - The net profit attributable to shareholders was 157 million yuan, reflecting a 1.0% increase from 155 million yuan in the same period last year [1]. - Gross margin decreased to 27.34%, down 20.74% year-on-year, while net margin slightly declined to 11.2%, a decrease of 0.51% [1]. - Total expenses (selling, administrative, and financial) amounted to 135 million yuan, representing 9.66% of revenue, a significant reduction of 45.77% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) remained stable at 0.11 yuan, with a slight increase of 0.95% year-on-year [1]. - The company's cash flow per share decreased to 0.37 yuan, down 38.21% from 0.60 yuan [1]. - The company's return on invested capital (ROIC) was reported at 4.33%, indicating weak capital returns in recent years [3]. Debt and Cash Flow Analysis - The company has a healthy cash position, with cash assets covering 87.19% of current liabilities [3]. - The interest-bearing debt decreased to 3.544 billion yuan, a reduction of 27.03% compared to the previous year [1]. - Accounts receivable increased to 1.382 billion yuan, a rise of 19.95% year-on-year, raising concerns about collection efficiency as accounts receivable to profit ratio reached 213.74% [3]. Market Dynamics - The company is closely monitoring the market for heparin active pharmaceutical ingredients (API), which are currently priced low, and is focused on maintaining its pricing structure [3].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has announced its first-quarter report for 2025, confirming the accuracy and completeness of the financial information disclosed [2][24]. Financial Data - The first-quarter report has not been audited [3][7]. - There are no adjustments or restatements required for previous accounting data [4]. - The company does not have any non-recurring profit and loss items [4]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders have been disclosed, with no changes reported in the lending of shares [6]. Board Meeting - The sixth board meeting of the company was held on April 24, 2025, with all seven directors participating and approving the first-quarter report [8][9]. - The board also approved an adjustment to the capital increase plan for its wholly-owned subsidiary, Tian Dao Pharmaceutical (Hong Kong) Co., Ltd., reducing the amount from USD 105 million to USD 31.92 million [11][12]. Subsidiary Capital Increase - The capital increase is aimed at expanding the sales and marketing network in the EU and other global markets [17][18]. - The adjustment to the capital increase plan was made in response to external market conditions and the company's global business development needs [18][22]. Product Approval - The company's subsidiary, Shenzhen Tian Dao Pharmaceutical Co., Ltd., received approval from the South African Health Products Regulatory Authority for its Enoxaparin Sodium Injection [25]. - This approval allows the company to sell its Enoxaparin Sodium products in the South African market, enhancing its global market share [26][28].

证券代码：002399 证券简称：海普瑞 公告编号：2025-023 深圳市海普瑞药业集团股份有限公司 第六届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 具体内容详见公司同日披露于《证券时报》《中国证券报》《上海证券报》《证 券日报》和巨潮资讯网www.cninfo.com.cn的《2025年第一季度报告》；及同日披露 于 香 港 联 合 交 易 所 有 限 公 司 网 站 http://www.hkexnews.hk 和 公 司 网 站 http://www.hepalink.com的H股《2025年第一季度业绩公告》。 2、《关于调整向全资子公司天道医药（香港）有限公司增资方案的议案》 表决结果：3票同意、0票弃权、0票反对。 公司于2021年12月10日召开的第五届董事会第十五次会议审议通过，公司决 定使用H股募集资金1.05亿美元以逐层增资的方式向全资子公司天道医药（香港） 有限公司增资，用于欧盟及其他全球市场拓展销售及营销网络以及基础设施的建 设。 根据外部市场环境结合公司全球业务发展的需求，决 ...